1. Medicines
  2. Neuroscience
  3. KESIMPTA® (ofatumumab)
  4. Dosing and administration

Dosing & Administration

KESIMPTA® offers the flexibility of a once monthly, at home dosing regimen¹*

Before starting KESIMPTA®¹:

  • Check immune status prior to initiating therapy. KESIMPTA® must not be given to patients in a severely immunocompromised state (e.g. significant neutropenia or lymphopenia).
  • Perform hepatitis B virus (HBV) screening
  • Vaccinate (at least 4 weeks prior for live or live-attenuated vaccines and at least 2 weeks prior for inactivated vaccines)

Dosing Regimen¹:

  • After initial doses*, KESIMPTA® is administered once monthly
  • The first injection should be performed under the guidance of a health care professional

Additional Information

  • If a dose of KESIMPTA® is missed, administer as soon as possible without waiting until the next scheduled dose; subsequent doses should be administered at the recommended intervals¹

*The initial dosing period consists of 20 mg SC doses at Weeks 0, 1, and 2.¹

†KESIMPTA® Sensoready® Pens must be refrigerated at 2ºC to 8ºC (36ºF to 46ºF). Keep product in the original carton to protect from light until the time of use.

Do not freeze. To avoid foaming, do not shake.¹

Click here for Product Information

References:
  1. KESIMPTA® SPC available at www.medicines.ie last accessed July 2022
Rate this content: 
No votes yet
IE224173 July 2022
Print
▼ This medicinal product is subject to additional monitoring. Reporting suspected adverse reactions of the medicinal product is important to Novartis and the HPRA. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported via HPRA Pharmacovigilance, website: www.hpra.ie. Adverse events could also be reported to Novartis preferably via www.report.novartis.com or by email: [email protected] or by calling 01 2080 612.

Reporting of side effects
Adverse events (side effects) can be reported via the HPRA. Reporting forms and information can be found at https://www.hpra.ie/homepage/about-us/report-an-issue. Adverse events could also be reported to Novartis preferably via www.report.novartis.com or by email: [email protected] or by calling (01) 2080 612. For information on any of our medicinal products please contact Medical Information on (01) 260 1255.

×

Ask Speakers

×

Medical Information Request